Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2011, 4(6), 804-821; doi:10.3390/ph4060804
Review

Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction

,  and *
Received: 2 May 2011; in revised form: 8 June 2011 / Accepted: 8 June 2011 / Published: 14 June 2011
(This article belongs to the Special Issue Drug Abuse Targets)
View Full-Text   |   Download PDF [137 KB, uploaded 14 June 2011]
Abstract: Drug addiction is a chronic illness characterized by high rates of relapse. Relapse to drug use can be triggered by re-exposure to drug-associated cues, stressful events, or the drug itself after a period of abstinence. Pharmacological intervention to reduce the impact of relapse-instigating factors offers a promising target for addiction treatment. Growing evidence has implicated an important role of the orexin/hypocretin system in drug reward and drug-seeking, including animal models of relapse. Here, we review the evidence for the role of orexins in modulating reward and drug-seeking in animal models of addiction and the potential for orexin receptors as specific targets for anti-relapse medication approaches.
Keywords: addiction; hypocretin; orexin; reinstatement; relapse addiction; hypocretin; orexin; reinstatement; relapse
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Zhou, L.; Sun, W.-L.; See, R.E. Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction. Pharmaceuticals 2011, 4, 804-821.

AMA Style

Zhou L, Sun W-L, See RE. Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction. Pharmaceuticals. 2011; 4(6):804-821.

Chicago/Turabian Style

Zhou, Luyi; Sun, Wei-Lun; See, Ronald E. 2011. "Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction." Pharmaceuticals 4, no. 6: 804-821.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert